June 23, 2014 (Shareholders Foundation) - An investigation on behalf of investors of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) shares over potential securities laws violations by Northwest Biotherapeutics and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) concerning whether a series of statements by Northwest Biotherapeutics. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Northwest Biotherapeutics, Inc reported that its annual Total Revenue rose from $0.01 million in 2011 to $0.81 million in 2013. Shares of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) grew from $3.21 per share in November 2013 to as high as $9.18 per share in March 2014, respectively $8.97 per share on June 18, 2014.

Then on June 19, 2014, an article was published that stated that 'The prestigious MD Anderson Cancer Center issued a stern rebuke to Northwest Biotherapeutics (NWBO) for making promotional, unjustified claims about results from an ongoing clinical trial of an experimental cancer vaccine known as DCVax-Direct.

Shares of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) declined to $6.78 per share on June 19, 2014.